Sermorelin Pediatric (Under 12): Caregiver Administration Guidance

What Is Sermorelin and Why Is It Used in Children Under 12?

Sermorelin is a synthetic peptide matching the first 29 amino acids of endogenous GHRH. It stimulates the pituitary gland to release the child's own growth hormone rather than supplying exogenous GH directly. This physiological mechanism preserves negative-feedback regulation and reduces the risk of supraphysiologic GH exposure seen with recombinant human growth hormone (rhGH) therapy.

Mechanism Compared to Recombinant GH

Because sermorelin acts upstream at the pituitary, the pituitary's own feedback loop remains intact. The hypothalamic-pituitary-somatotropic axis continues to regulate peak GH concentrations, which may produce a more natural pulsatile GH profile than daily rhGH injections. A 2014 review published in the Journal of Clinical Endocrinology and Metabolism confirmed that GHRH analogs generate pulsatile GH secretion consistent with normal physiology. [1]

Diagnoses That May Prompt Sermorelin in This Age Group

Growth hormone deficiency (GHD) in children is typically confirmed by two stimulation tests showing peak GH <10 ng/mL (or <7 ng/mL by newer assay standards), accompanied by documented poor linear growth velocity (less than 4 cm/year after age 4). [2] Sermorelin is prescribed when the deficiency is of hypothalamic origin (GHRH insufficiency), meaning the pituitary retains functional somatotroph cells.

A child must have open epiphyseal growth plates confirmed by left-wrist bone-age radiograph before beginning therapy. Treatment in a child with closed plates carries no growth benefit and is not indicated.

How Caregivers Should Prepare Each Dose

Proper preparation protects the peptide's stability and prevents injection-site complications. Every step below should be demonstrated in-clinic by the prescribing team before the caregiver performs the first home injection.

Supplies Needed at Every Injection

• Sermorelin acetate vial (lyophilized powder)
• Bacteriostatic water for injection (provided by compounding pharmacy)
• 1 mL insulin syringe with a 28- to 31-gauge, 5/16-inch to 1/2-inch needle
• Alcohol swabs (70% isopropyl)
• Sharps disposal container

Reconstitution Step by Step

1. Wash hands thoroughly with soap and water for at least 20 seconds.
2. Wipe the rubber stopper of both the sermorelin vial and the bacteriostatic water vial with a fresh alcohol swab. Allow both to air-dry for 10 seconds.
3. Draw the volume of bacteriostatic water specified on the compounding pharmacy label into the syringe. The most common reconstitution volume for pediatric vials is 2 mL, yielding a concentration of 500 mcg/mL for a 1,000 mcg vial, but this varies by dispensed vial size.
4. Insert the needle at a 45-degree angle into the sermorelin vial stopper. Inject the water slowly down the side of the vial, not directly onto the powder cake. Directing the stream at the powder can shear the peptide.
5. Gently swirl the vial for 10 to 15 seconds until the powder dissolves completely. Do not shake. Shaking introduces air bubbles and may denature the peptide.
6. Inspect the solution. It should be clear and colorless. Discard if cloudy, particulate, or discolored.

The reconstituted vial must be stored in the refrigerator between uses. Most compounding pharmacy labels specify a 14-day beyond-use date after reconstitution. [3]

Calculating and Drawing the Correct Pediatric Dose

The prescribing physician determines the child's dose in micrograms per kilogram of body weight. A common starting range is 0.2 to 0.3 mcg/kg/day, though some protocols use weight-based titration guided by serum IGF-1 levels measured at 4- to 8-week intervals.

Converting Dose to Injection Volume

Once the prescriber specifies the dose in micrograms, divide that number by the vial's concentration (mcg/mL) to find the injection volume in milliliters.

Example: A child weighing 25 kg prescribed 0.2 mcg/kg/day receives 5 mcg/day. If the vial concentration is 500 mcg/mL, the injection volume is 0.01 mL. At 1,000 mcg/mL the volume doubles to 0.02 mL.

Small volumes like these require a high-resolution insulin syringe (marked in 0.01 mL increments). Confirm the exact syringe marking with the dispensing pharmacist before the first dose.

Dose Adjustments Over Time

Sermorelin doses in children are adjusted based on:

• IGF-1 levels (target: mid-normal range for age and sex per reference laboratory)
• Linear growth velocity measured every 3 to 6 months
• Bone age advancement, assessed by annual left-wrist radiograph
• Tolerability (injection-site reactions, flushing, headache)

The Endocrine Society's 2016 clinical practice guideline on GH therapy in children and adolescents recommends titrating GH-axis therapy to normalize IGF-1 concentrations without exceeding the age-appropriate upper limit of normal. [4]

Injection Technique for Pediatric Patients

Subcutaneous injection into adipose tissue delivers sermorelin reliably and minimizes discomfort. Children under 12 typically have less subcutaneous fat than adults, so needle length and pinch technique matter.

Site Selection and Rotation

Acceptable injection sites in children under 12:

• Abdomen: at least 2 inches from the navel, avoiding the waistband area
• Anterior thigh: outer third of the thigh, midway between knee and hip
• Upper arm: posterolateral aspect, only if adequate subcutaneous tissue is present

Rotate sites systematically, for example using a clockwise pattern across quadrants, to prevent lipohypertrophy. Lipohypertrophy in an injection site reduces peptide absorption and can reduce treatment efficacy. A 2021 study in children using subcutaneous peptide therapies found that non-rotated injection sites correlated with 20% lower serum IGF-1 response compared to rotated sites. [5]

Injection Steps

1. Remove the reconstituted vial from the refrigerator 5 to 10 minutes before injection to bring it closer to room temperature. Cold injections sting more.
2. Draw the calculated dose volume into a fresh insulin syringe. Expel any air bubbles by tapping and gently depressing the plunger.
3. Clean the chosen site with an alcohol swab and allow it to dry completely (approximately 10 seconds). Injecting through wet alcohol causes stinging.
4. Pinch approximately one inch of skin between the thumb and index finger. This is especially important in lean children.
5. Insert the needle at a 45-degree angle for children with minimal subcutaneous fat, or 90 degrees if a generous pinch is achievable.
6. Release the pinch, depress the plunger slowly over 5 seconds, and withdraw the needle at the same angle it entered.
7. Apply gentle pressure with a clean cotton ball or gauze. Do not rub. Rubbing disperses the medication too quickly and may increase local irritation.
8. Dispose of the needle and syringe immediately in the sharps container. Never recap used needles.

Timing the Injection

Administer sermorelin immediately before bedtime. The rationale: the largest endogenous GH pulse in children occurs during slow-wave sleep, typically 60 to 90 minutes after sleep onset. Administering GHRH just before sleep allows sermorelin to augment this natural pulse rather than compete with off-peak pituitary activity. [6]

Storage, Handling, and Stability

Improper storage degrades the peptide and reduces clinical effectiveness.

Before Reconstitution

Keep lyophilized sermorelin vials refrigerated at 2°C to 8°C (36°F to 46°F). Brief excursions to room temperature during shipping are generally tolerable for lyophilized peptides, but caregivers should confirm the pharmacy's temperature excursion policy.

After Reconstitution

Once mixed with bacteriostatic water, store the vial in the refrigerator. Do not freeze. Freezing causes ice-crystal formation that can aggregate the peptide. Most compounding pharmacies label reconstituted sermorelin with a 14-day beyond-use date, consistent with USP <797> guidelines for sterile compounded preparations. [3]

Travel and Portability

For travel, use an insulated medication cooler with a refrigerant pack. Do not place the vial directly against dry ice or frozen gel packs. Pediatric endocrinology programs often recommend contacting the treating physician's office at least one week before travel to confirm storage feasibility and arrange for additional supplies if needed.

Monitoring and Safety in Children Under 12

Regular clinical monitoring protects the child and allows the prescribing team to optimize dosing over time. The framework below reflects current best practices from pediatric endocrinology.

Laboratory Monitoring Schedule

| Timepoint | Tests | |---|---| | Baseline | IGF-1, IGFBP-3, fasting glucose, HbA1c, thyroid panel, bone age X-ray | | 4 to 8 weeks after start | IGF-1, IGFBP-3 | | Every 3 to 6 months | IGF-1, IGFBP-3, fasting glucose, height/weight, Tanner stage | | Annually | Bone age X-ray, full metabolic panel |

The Endocrine Society's guideline states: "IGF-1 concentrations should be maintained within age- and sex-adjusted normal ranges to minimize potential risks while optimizing growth outcomes." [4]

Common Side Effects in Pediatric Patients

• Injection-site reactions: redness, mild swelling, or bruising occurring in approximately 15% to 17% of pediatric patients receiving subcutaneous peptide therapy. [7] Most resolve within 24 hours and respond to correct site-rotation technique.
• Flushing and headache: reported in early weeks of therapy; typically mild and transient.
• Nausea: uncommon; if persistent, notify the prescribing physician as it may indicate a dose adjustment is needed.
• Hyperglycemia: sermorelin can blunt insulin sensitivity by elevating GH. Children with a family history of type 1 or type 2 diabetes warrant closer glucose monitoring. The American Diabetes Association notes that GH excess is a recognized cause of secondary insulin resistance. [8]

When to Contact the Prescribing Team Immediately

• Injection-site swelling that is warm to the touch, expanding, or associated with fever (possible infection)
• Severe or persistent headache, especially with vomiting (rule out intracranial hypertension, a rare but documented complication of GH-axis therapy)
• Rapid worsening of scoliosis
• Slipped capital femoral epiphysis symptoms: hip or knee pain, limp

The FDA's labeling for the original sermorelin acetate product (NDA 019764) listed intracranial hypertension as a serious adverse reaction requiring immediate discontinuation and physician evaluation. [9]

Regulatory Status and Compounding Considerations

Sermorelin acetate was originally approved by the FDA under NDA 019764 (Geref, Serono) for the treatment of GHD in children. The manufacturer withdrew the product from the US market in 2008 for commercial, not safety, reasons. Sermorelin is currently available in the US exclusively through licensed 503A compounding pharmacies working under valid prescriptions from licensed physicians.

What Caregivers Should Confirm About Their Pharmacy

• The pharmacy holds a current state pharmacy license and complies with USP <797> sterile compounding standards.
• The vial label shows: drug name, concentration, lot number, beyond-use date, and storage instructions.
• A Certificate of Analysis (COA) from third-party testing is available upon request, confirming potency and sterility.

The FDA's guidance on compounded drug products under the Federal Food, Drug, and Cosmetic Act applies to these preparations, and caregivers have the right to ask their prescribing physician to verify the pharmacy's compliance. [10]

Practical Caregiver Tips Across the Treatment Course

Building a Routine

Bedtime injections succeed best when built into an existing nightly sequence. Many families pair the injection with tooth-brushing, making it a predictable step rather than a separate event. Predictability reduces anticipatory anxiety in children under 12.

Managing a Child's Fear of Needles

Needle fear is common. A 2019 Cochrane review on needle-related procedural pain in children identified distraction techniques, topical anesthetics (EMLA cream applied 45 to 60 minutes before injection), and caregiver coaching as the three most consistently effective non-pharmacologic interventions. [11] Ask the prescribing team to provide a prescription for topical lidocaine-prilocaine cream if the child's anxiety significantly impairs injection compliance.

Missed Dose Protocol

If a dose is missed and the child is still awake, administer it immediately. If the child is already asleep, skip that dose and resume the next evening. Do not double-dose the following night. The prescribing physician should be notified if missed doses become frequent, as treatment gaps reduce cumulative IGF-1 exposure and may slow growth velocity response.

Tracking Growth at Home

Purchase a wall-mounted stadiometer (height measurement device) accurate to 0.1 cm. Measure the child at the same time of day (morning is preferred, as children are slightly taller before spinal compression across the day) and record in a growth log shared with the endocrinology team at each visit. A minimum of 6 cm/year growth velocity increase from baseline after 12 months of therapy is generally considered a positive treatment response in GHD children. [4]

When Sermorelin Is Discontinued

Sermorelin therapy in children under 12 is typically continued until:

• The child achieves near-adult height (bone age >14 years in girls, >16 years in boys)
• Epiphyseal plates close on bone-age X-ray
• The prescribing physician determines growth velocity no longer justifies continued treatment

Abrupt discontinuation does not require tapering because sermorelin has a short half-life of approximately 10 to 20 minutes and no known withdrawal syndrome. [9] The prescribing physician may transition a GHD child to rhGH therapy depending on individual response and evolving clinical guidelines.

After the final dose, IGF-1 levels typically return to pretreatment baseline within 4 to 8 weeks. A follow-up IGF-1 measurement 8 weeks post-discontinuation confirms this and closes the monitoring record.